Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis

M. Tomcik, K. Palumbo-Zerr, P. Zerr, B. Sumova, J. Avouac, C. Dees, A. Distler, R. Becvar, O. Distler, G. Schett, L. Senolt, JH. Distler,

. 2016 ; 75 (3) : 609-16. [pub] 20150120

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020994

OBJECTIVES: Tribbles homologue 3 (TRB3) is a pseudokinase that modifies the activation of various intracellular signalling pathways to control fundamental processes extending from mitosis and cell activation to apoptosis and modulation of gene expression. Here, we aimed to analyse the role of TRB3 in fibroblast activation in systemic sclerosis (SSc). METHODS: The expression of TRB3 was quantified by quantitative PCR, western blot and immunohistochemistry. The role of TRB3 was analysed in cultured fibroblasts and in experimental fibrosis using small interfering RNA (siRNA)-mediated knockdown and overexpression of TRB3. RESULTS: TRB3 expression was increased in fibroblasts of patients with SSc and in murine models of SSc in a transforming growth factor-β (TGF-β)/Smad-dependent manner. Overexpression of TRB3 stimulated canonical TGF-β signalling and induced an activated phenotype in resting fibroblasts. In contrast, knockdown of TRB3 reduced the profibrotic effects of TGF-β and decreased the collagen synthesis. Moreover, siRNA-mediated knockdown of TRB3 exerted potent antifibrotic effects and ameliorated bleomycin as well as constitutively active TGF-β receptor I-induced fibrosis with reduced dermal thickening, decreased hydroxyproline content and impaired myofibroblast differentiation. CONCLUSIONS: The present study characterises TRB3 as a novel profibrotic mediator in SSc. TGF-β induces TRB3, which in turn activates canonical TGF-β/Smad signalling and stimulates the release of collagen, thereby inducing a positive feedback loop that may contribute to aberrant TGF-β signalling in SSc.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020994
003      
CZ-PrNML
005      
20160725112635.0
007      
ta
008      
160722s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/annrheumdis-2014-206234 $2 doi
024    7_
$a 10.1136/annrheumdis-2014-206234 $2 doi
035    __
$a (PubMed)25603829
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tomcik, Michal $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany Department of Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
245    10
$a Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis / $c M. Tomcik, K. Palumbo-Zerr, P. Zerr, B. Sumova, J. Avouac, C. Dees, A. Distler, R. Becvar, O. Distler, G. Schett, L. Senolt, JH. Distler,
520    9_
$a OBJECTIVES: Tribbles homologue 3 (TRB3) is a pseudokinase that modifies the activation of various intracellular signalling pathways to control fundamental processes extending from mitosis and cell activation to apoptosis and modulation of gene expression. Here, we aimed to analyse the role of TRB3 in fibroblast activation in systemic sclerosis (SSc). METHODS: The expression of TRB3 was quantified by quantitative PCR, western blot and immunohistochemistry. The role of TRB3 was analysed in cultured fibroblasts and in experimental fibrosis using small interfering RNA (siRNA)-mediated knockdown and overexpression of TRB3. RESULTS: TRB3 expression was increased in fibroblasts of patients with SSc and in murine models of SSc in a transforming growth factor-β (TGF-β)/Smad-dependent manner. Overexpression of TRB3 stimulated canonical TGF-β signalling and induced an activated phenotype in resting fibroblasts. In contrast, knockdown of TRB3 reduced the profibrotic effects of TGF-β and decreased the collagen synthesis. Moreover, siRNA-mediated knockdown of TRB3 exerted potent antifibrotic effects and ameliorated bleomycin as well as constitutively active TGF-β receptor I-induced fibrosis with reduced dermal thickening, decreased hydroxyproline content and impaired myofibroblast differentiation. CONCLUSIONS: The present study characterises TRB3 as a novel profibrotic mediator in SSc. TGF-β induces TRB3, which in turn activates canonical TGF-β/Smad signalling and stimulates the release of collagen, thereby inducing a positive feedback loop that may contribute to aberrant TGF-β signalling in SSc.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorová antibiotika $x toxicita $7 D000903
650    _2
$a bleomycin $x toxicita $7 D001761
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a proteiny buněčného cyklu $x genetika $x metabolismus $7 D018797
650    _2
$a kultivované buňky $7 D002478
650    _2
$a kolagen $x metabolismus $7 D003094
650    _2
$a škára $x cytologie $7 D020405
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblasty $x metabolismus $7 D005347
650    _2
$a fibróza $x chemicky indukované $x genetika $7 D005355
650    _2
$a genový knockin $7 D055879
650    _2
$a genový knockdown $7 D055785
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a lidé středního věku $7 D008875
650    _2
$a protein-serin-threoninkinasy $x antagonisté a inhibitory $x genetika $x metabolismus $7 D017346
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a receptory transformujícího růstového faktoru beta $7 D018125
650    _2
$a represorové proteiny $x genetika $x metabolismus $7 D012097
650    _2
$a systémová sklerodermie $x genetika $x metabolismus $7 D012595
650    _2
$a signální transdukce $x genetika $7 D015398
650    _2
$a kožní nemoci $x chemicky indukované $x genetika $7 D012871
650    _2
$a protein Smad3 $x metabolismus $7 D051900
650    _2
$a transformující růstový faktor beta $x metabolismus $7 D016212
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Palumbo-Zerr, Katrin $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Zerr, Pawel $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Sumova, Barbora $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany Department of Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
700    1_
$a Avouac, Jerome $u Rheumatology A Department, Paris Descartes University, Cochin Hospital, Paris, France. $7 gn_A_00010388
700    1_
$a Dees, Clara $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Distler, Alfiya $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Becvar, Radim $u Department of Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
700    1_
$a Distler, Oliver $u Center of Experimental Rheumatology and Zurich Center of Integrative Human Physiology, University Hospital, Zurich, Switzerland.
700    1_
$a Schett, Georg $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Senolt, Ladislav $u Department of Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University, Prague, Czech Republic.
700    1_
$a Distler, Jörg H W $u Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
773    0_
$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 75, č. 3 (2016), s. 609-16
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25603829 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160725112853 $b ABA008
999    __
$a ok $b bmc $g 1155664 $s 945522
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 75 $c 3 $d 609-16 $e 20150120 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
LZP    __
$a Pubmed-20160722
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace